WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/024237    International Application No.:    PCT/CN2017/095884
Publication Date: 08.02.2018 International Filing Date: 03.08.2017
C07K 16/28 (2006.01), C12N 15/13 (2006.01), C12N 15/85 (2006.01), A61K 39/395 (2006.01), A61K 51/10 (2006.01), A61P 35/00 (2006.01)
Applicants: INNOVENT BIOLOGICS (SUZHOU) CO., LTD [CN/CN]; 168 Dongping Street, Suzhou Industrial Park Suzhou, Jiangsu 215123 (CN)
Inventors: SHEN, Xiaoning; (CN).
MIAO, Xiaoniu; (CN).
LIU, Xiaolin; (CN)
Agent: XU & PARTNERS,LLC.; Room No.106, Building No.1 Universal High-Tech Plaza 958 Zhen Bei Road, Putuo District Shanghai 200333 (CN)
Priority Data:
201610634596.X 04.08.2016 CN
(ZH) 抗PD-L1纳米抗体及其应用
Abstract: front page image
(EN)Disclosed is a nanobody against the human programmed death factor PD-L1. The antibody has the function of blocking the binding of PD-L1 to the receptor PD-1. Disclosed are the nanobody and the gene sequence encoding the nanobody, the corresponding expression vector and the host cell capable of expressing the nanobody, and the method for producing the nanobody. At the same time, also disclosed is the sequence of the humanized PD-L1 nanobody. The humanized nanobody still has the function of blocking the binding of PD-L1 to PD-1, and has a relatively high affinity and a relatively good specificity.
(FR)L'invention concerne un nanocorps contre le facteur de mort humain programmé PD-L1. L'anticorps a pour fonction de bloquer la liaison de PD-L1 au récepteur PD-1. L'invention concerne le nanocorps et la séquence de gènes codant pour le nanocorps, le vecteur d'expression correspondant et la cellule hôte capables d'exprimer le nanocorps, et le procédé de production du nanocorps. En même temps, l'invention concerne également la séquence du nanocorps humain PD-L1. Le nanocorps humanisé a encore la fonction de bloquer la liaison de PD-L1 à PD-1, et a une affinité relativement élevée et une spécificité relativement bonne.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)